Literature DB >> 32335323

Consensus on resectability in N3 head and neck squamous cell carcinomas: GETTEC recommendations.

Florent Carsuzaa1, Philippe Gorphe2, Sébastien Vergez3, Olivier Malard4, Nicolas Fakhry5, Christian Righini6, Pierre Philouze7, Audrey Lasne-Cardon8, Patrice Gallet9, Denis Tonnerre1, Alexandre Bozec10, Erwan de Mones11, Bertrand Baujat12, Laurent Laccourreye13, Emmanuel Babin8, Xavier Dufour1, Juliette Thariat14.   

Abstract

BACKGROUND: Among patients with T0-2 N3 head and neck squamous cell carcinomas (HNSCC), those undergoing upfront neck dissection have better oncological outcomes. However, there is no consensual definition of disease resectability of N3 nodes, leading to major treatment attrition and interpretation biases between studies. We established a Delphi method-based consensus to define resectability and impact on decision-making for upfront neck dissection in N3 patients.
METHODS: The Delphi method was designed as recommended by the French Haute Autorite de Sante among head and neck surgeons from university hospitals and cancer centers, using a 24-item questionnaire. Strong and relative agreements were subsequently established, and recommendations were written. The resulting recommendations were assessed by 30 independent surgeons.
RESULTS: N3 nodes with intraparenchymal brain invasion, foramen invasion, skull base erosion, nodes requiring bilateral XIIth cranial nerve sacrifice, retropharyngeal N3 node or a node above the plan of soft palate are major contraindications to neck dissection. When neck dissection requires unilateral sacrifice of the IXth or Xth or XIIth cranial nerves or cervical nerve roots, upfront neck dissection may be performed, based on a case-by-case assessment of other patient and tumor estimates.
CONCLUSION: Consensual contraindications to neck dissection in patients with T0-2 N3 HNSCC were defined among French head and neck surgeons as concerns skull base invasion, retropharyngeal nodes and bilateral XIIth cranial nerve sacrifice. This consensus should allow more reliable comparisons between surgical and non-surgical strategies in N3 patients.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cervical nodes; Chemoradiation; Contraindication; Head and neck squamous cell carcinoma; Neck dissection; Surgery

Year:  2020        PMID: 32335323     DOI: 10.1016/j.oraloncology.2020.104733

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  3 in total

1.  Resection and reconstruction of the carotid artery for head and neck squamous cell carcinoma: a GETTEC study.

Authors:  Yonjae Kim; Pierre Philouze; Olivier Malard; Xavier Dufour; Lara Nokovitch; Philippe Céruse; Philippe Zrounba; Charles Maquet; Sophie Deneuve
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-03-31       Impact factor: 3.236

Review 2.  Reporting quality of clinical practice guidelines on head and neck cancer: a systematic review.

Authors:  Jiabao Hou; Qiangqiang Guo; Hanqiong Zhou; Xuan Wu; Lidan Hao; Zhe Zhang; Shuxiang Ma; Jing Han; Zhen He; Zhensheng Liu; Yaolong Chen; Qiming Wang
Journal:  Transl Cancer Res       Date:  2022-06       Impact factor: 0.496

3.  Impact of Neck Dissection in Head and Neck Squamous Cell Carcinomas of Unknown Primary.

Authors:  Yazan Abu-Shama; Julia Salleron; Florent Carsuzaa; Xu-Shan Sun; Carole Pflumio; Idriss Troussier; Claire Petit; Matthieu Caubet; Arnaud Beddok; Valentin Calugaru; Stephanie Servagi-Vernat; Joël Castelli; Jessica Miroir; Marco Krengli; Paul Giraud; Edouard Romano; Jonathan Khalifa; Mélanie Doré; Nicolas Blanchard; Alexandre Coutte; Charles Dupin; Shakeel Sumodhee; Yungan Tao; Vincent Roth; Lionel Geoffrois; Bruno Toussaint; Duc Trung Nguyen; Jean-Christophe Faivre; Juliette Thariat
Journal:  Cancers (Basel)       Date:  2021-05-17       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.